AUTUMN WORK: Open Payments
NPI 1275241051 · LINDSAY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$447 in 24 payments from 12 companies in 2025. Trend: 2023 $104 · 2024 $237 · 2025 $447
Food & beverage: $447
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $138 |
| Lilly USA, LLC | 3 | $56 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| ABBVIE INC. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Biogen, Inc. | 1 | $15 |
Products named: Ozempic, Rybelsus, MOUNJARO, CAPLYTA, BREZTRI, Kerendia, GEMTESA, VRAYLAR.
Industry payments across OK — which companies pay providers there.
